Prospective trial of ivermectin, dexamethasone, enoxaparin, and aspirin.
There was one death from 167 patients for 0.59% mortality, compared to an estimated overall mortality rate in Argentina of 2.1%.
For moderate to severe cases needing hospitalization, only 1 patient out of 32 died, authors compare to published rates of ~25%. There was 12 patients in the same hospital that were not treated with a 25% mortality rate.
Carvallo et al., 9/15/2020, prospective, Argentina, South America, preprint, mean age 55.7, 3 authors, dosage 36mg days 1, 8, dose varied depending on patient condition - mild 24mg, moderate 36mg, severe 48mg, this trial uses multiple treatments in the treatment arm (combined with dexamethasone, enoxaparin, and aspirin) - results of individual treatments may vary.
risk of death for hospitalized cases in study vs. cases in the same hospital not in the study, 87.9% lower, RR 0.12, p = 0.05, treatment 1 of 33 (3.0%), control 3 of 12 (25.0%), the only treatment death was a patient already in the ICU before treatment.
Effect extraction follows pre-specified rules
prioritizing more serious outcomes. For an individual study the most serious
outcome may have a smaller number of events and lower statistical signficance,
however this provides the strongest evidence for the most serious outcomes
when combining the results of many trials.